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ABSTRACT
Background & objectives: Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) are responsible for most of
the global burden of malaria. With changing spectrum of clinical presentation in malaria, pulmonary system
involvement has always been under diagnosed. The present study was planned to estimate the pulmonary system
involvement in patients with malaria from north-western India (Bikaner).
Study design & description of the patients: Our study was conducted during 2007 to 2009 in 200 cases of severe
malaria [Pf , Pv, and mixed (Pf + Pv)] with pulmonary involvement. It included adult patients of both sexes (145
males and 55 females) belonging to all age groups. The diagnosis of Pf and Pv was confirmed by demonstrating
asexual form of parasites in peripheral blood smear and OptiMal test.
Main outcome measures: Pulmonary involvement was observed in 30% (60/200) patients among which cough in
24% , dyspnea in 12%, acute respiratory distress syndrome (ARDS) in 7% , bronchitis in 3% and pneumonia in
1.5% were the major clinical manifestations of malaria. Metabolic acidosis and low oxygen saturation was
observed in 7% patients. Chest X-ray abnormality in 11.5% patients, 7% had bilateral infiltrates, 1.5% had
inflammatory patch and 3% had findings suggestive of bronchitis. Spirometry findings showed 17% patients
had early small airway obstruction. All the patients with ARDS had poor disease outcome.
Results & conclusion: Our results suggest that pulmonary system involvement was observed in patients infected
with Pf and Pv. If these clinical presentations are ignored, it may lead to delay in diagnosis and can alter the
outcome and prognosis of the disease. Therefore, early diagnosis of malaria induced ARDS can significantly
affect the outcome.
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INTRODUCTION
Plasmodium falciparum and P. vivax are responsible
for most of the global burden of malaria. More than two
billion people are at the risk of contracting malaria1, espe-
cially in the tropical and subtropical countries. Recent
epidemiologic models, geographical and demographic data
suggest that in India about two million confirmed cases
and 1000 deaths are reported annually, although 15 mil-
lion cases and 20,000 deaths are estimated by WHO-South
East Asia Regional Office (SEARO), India. In the South-
eastern Asian Region of WHO, of ~1.4 billion people liv-
ing in 11 countries (land area, 8,466,600 km2; i.e. 6% of
global area), 1.2 billion are exposed to the risk of malaria,
most of whom live in India. However, Southeast Asia con-
tributed to only 2.5 million cases to the global burden of
malaria. Of this, India alone contributed 76% of total
cases2.
Usually patients with uncomplicated malaria present
with fever and non-specific symptoms, complicated and
severe malaria can cause multiorgan involvement includ-
ing acute respiratory distress syndrome (ARDS)3. The
spectrum of severe malaria has changed worldwide as well
as in India4. Important clinical features include acute non-
cardiogenic pulmonary edema, ARDS, acute lung injury
(ALI) and intestinal pneumonia. Anstey et al5 demonstrated
that clinically uncomplicated cases of both P. falciparum
and P. vivax malaria presented with compromised pulmo-
nary functions including small airway obstruction, gas
exchange alterations and increased pulmonary phagocytic
activity. Maguire et al6 observed that in uncomplicated
and severe P. falciparum malaria, pulmonary vascular
occlusion occurs. However, impaired alveolar-capillary
membrane functions were seen in patients with severe
malaria. In contrast to falciparum malaria, vivax malaria
is rarely associated with serious complications. It was pre-
sumed that P. vivax infection may lead to severe conse-
quences only when possibility of mixed infections exists7
and the pulmonary manifestations were so far under-diag-
nosed. ARDS was observed as have drastic onset in pa- J Vector Borne Dis 48, December 2011 220
tients infected with P. vivax malaria and required immedi-
ate life-support4.
Bikaner district is a part of the Thar Desert, India
having extremes of temperature. This region has always
been regarded as hypoendemic area for malaria. This is
basically an arid zone, which had recently experienced
changes in ecosystem due to increased rainfall and canal
irrigation in the last two decades. The scenario of both
disease morbidity and mortality has altered to a great ex-
tent during the past decades. Reports of malaria cases in
1995 showed that 3.18% of total malaria cases and 0.28%
of total P. falciparum cases were reported from Rajasthan
(Source: NVBDCP). There are increasing reports of mul-
tiple organ dysfunctions and severe pulmonary syndrome
in falciparum malaria3,8. However, meagre reports have
been found for pulmonary manifestation in P. vivax in-
fected patients4,9,10. Therefore, the aim of the present
clinico-epidemiological study was to assess the incidence,
clinical profile and outcome for respiratory system mani-
festation of malaria.
MATERIAL & METHODS
Patients and study site
This study was conducted on 200 patients with ma-
laria. The cases were selected randomly amongst all the
patients of malaria admitted other than those in exclusion
criteria. The patients of both sexes were irrespective of
age, except the pediatric age group. The diagnosis of ma-
laria was confirmed by examination of thick and thin
smear/OptiMal test. Only those cases with asexual forms
of Plasmodium in the blood by smear examination or found
positive in OptiMal test for Plasmodium were included.
The peripheral blood films were prepared from prick of
finger, stained by conventional Leishman’s stain and
Geimsa stain seen under oil immersion (100×) taking care
to examine particular upper and lower margins and tail
end of the film (because the parasites are numerous there)
and a minimum of 100 fields were examined before de-
claring the slides negative for Plasmodium. The patients
with any other systemic disease, chronic respiratory dis-
ease, chronic obstructive pulmonary disease, bronchitis,
and pulmonary tuberculosis were excluded from study.
Smokers, pregnant or lactating females and those unable
to give informed consent were also excluded.
Clinical and pulmonary function assessment
Clinical history for all patients was properly taken.
All patients underwent detailed laboratory investigation,
which included hemoglobin, total and differential leuko-
cyte count, platelet count, serum bilirubin, serum asparate
aminotransferase and alanine aminotransferase, blood
sugar, serum creatinine, blood urea, serum electrolyte,
complete urine examination. ECG, X-ray chest, ultrasound
abdomen, pulse oxymetry, blood gas analysis and pulmo-
nary function tests were done in selected patients.
All patients received uniform drug regimen in the form
of either artesunate 2.4 mg/kg over 10 min followed by 2.4
mg/kg every 24 h or I.V. quinine (20 mg/kg) loading dose
over 4 h in Day 1 then 10 mg/kg at 8 hourly for a total of 7
days of therapy. Antibiotics were given in selected patients
those who required. Oxygen therapy was given in patients
who required. All the patients of ARDS were given ventila-
tor support. Follow-up was done on Day 14.
Ethical approval and informed consent
The study was ethically approved by the institutional
ethics committee within the framework of the larger project.
Patients or patient’s guardians were asked for written in-
formed consent by the research nurse. Moreover, the pro-
cedure performed (systemic clinical examination and his-
tory, and diagnostic test for malaria) provided patients
with a laboratory-confirmed diagnosis of malaria and con-
sequently with better management of the disease.
RESULTS
The study was conducted on 200 adult malaria pa-
tients [Males = 145 (72.5%); Females = 55 (27.5%)] ad-
mitted during 2007–09. In our study, 80 (40%), 80 (40%)
and 40 (20%) cases were infected with P. falciparum, P.
vivax, and mixed infections (Pf + Pv), respectively. Dis-
tribution of malaria cases [P. falciparum, P. vivax, and
mixed (Pf + Pv)] according to age showed that maximum
patients 113 (56.5%) were in the age group of 21–40 yr.
The minimum number of malaria cases 16 (8%) were in
the age group >60 yr.
Respiratory system involvement was observed in 60
(30%) malaria patients. Of these, 43 (21.5%), 14 (7%),
and 3 (1.5%) were infected with P. falciparum, P. vivax,
and mixed infections (Pf + Pv), respectively. The different
pulmonary manifestations are presented in Table 1. In
patients with respiratory involvement, 48 (24%) malaria
patients presented with cough, out of which 32 (16%) had
dry cough. The majority 44 (22%) were infected by P.
falciparum malaria, 3 with P. vivax. Respiratory rate of
maximum patients (64%) ranged between 14 and 18
breaths/min. Fourteen (7%) patients had respiratory rate
>25, out of which 9 were infected with P. falciparum ma-
laria. Pneumonitis (as per WHO guidelines) was observed
in 3 patients. Six patients had acute bronchitis, out of which
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infections (Pf + Pv). ARDS (as per WHO guidelines) was
presented in 14 of malaria patients, out of which 9 were of
P. falciparum and 4 were infected with P. vivax. Dyspnea
was observed in 24 patients. Abnormal chest X-ray was
presented in 23 patients infected with malaria. Fourteen
had infiltrate, 3 had inflammatory patch and 6 had find-
ings suggestive of bronchitis.
Early airway obstruction was observed in 34 cases as
assessed by spirometry, out of which 16 were infected with
P. falciparum and 10 with P. vivax. Ten patients showed
reversibility after salbutamol (200 μg) inhalation after two
minutes. Twenty-four patients showed no effect of medi-
cation. Repeating the spirometry after 14 days showed
that 10 had persistence of early small airway obstruction.
Metabolic acidosis was present in 14 malaria patients as
assessed by blood gas analysis. Oxygen saturation in maxi-
mum 14 ranged between 96 and 100%.
Severe anaemia (haemoglobin < 5 mg%) was observed
in 67 (33.5%), out of which 28 were infected with P.
falciparum, 26 with P. vivax, and 13 were mixed infec-
tions (Pf + Pv). Total leukocyte count (TLC) in range of
4000–11000/μl was observed in 182 (91%) patients. Jaun-
dice was present in 68 (29%), out of which 12% were P.
falciparum and 10% were infected with P. vivax and 7%
were mixed (Pf + Pv) infections. Eighteen patients had
serum creatinine >3 mg/dl and 16 had blood urea around
100 mg/dl. Outcome of malaria patients with respiratory
system involvement showed that 46 (23%) recovered and
14 (7%) expired.
DISCUSSION
With spurt in developmental activities in the Bikaner
region (north-western India), marked changes in epide-
miological and clinical profile of malaria over last few
decades has been observed. Although pulmonary mani-
festation has invariably been reported in P. falciparum
malaria but its association with P. vivax is also been no-
ticed recently. In India, about 70% infections are reported
due to P. vivax, 25.3% due to P. falciparum and 4–8%
due to mixed infections. Although our study do not reflect
the true prevalence of P. falciparum and P. vivax in the
community as most of our patients were from Bikaner City,
others were complicated cases referred from primary health
centers situated in rural areas with semi developed medi-
cal facilities. In this study, 16.67% of total cases were
from urban area of Bikaner and one fourth (25%) of cases
were complicated and referred from primary health cen-
ters in Bikaner, which are the main pockets of existence of
P. falciparum malaria.
Gozal11has conducted a study on 50 P. falciparum
infected patients and dyspnea was observed in 2. Mishra
& Ray12 conducted a study on 150 cases in which 72 (48%)
were P. vivax, 54 (36%) of P. falciparum, and 24 (16%)
were mixed infections. Forty-five patients had respiratory
symptom involvement and 40% of these have dyspnea, of
these 45 patients 42 (93.4%) were of P. falciparum ma-
laria. In a study done by Rajput et al13 on 100 patients (53
P. vivax; 36 P. falciparum and 11 mixed infections), 26/
100 had respiratory involvement. Incidence of dyspnea in
our study was comparable to those observed by Mishra &
Ray12 and Rajput et al13, however, we noticed an increased
incidence of dyspnea in patients of P. vivax.
In recent years, incidence of pulmonary manifesta-
tion has increased in patients with malaria11. The present
study results are in conformity with the findings of other
studies by Anstey et al5, Mishra & Ray12, and Gozal11,
however, an increased incidence was observed in those
Table 1. Distribution of pulmonary manifestations (clinical and laboratory) in relation to patients of different types of malaria
Pulmonary manifestation Types of malaria     Total
  No. (%)
P.  falciparum P. vivax Mixed infections (Pf + Pv)
No. (%) No. (%) No. (%)
Cough 44 (22) 3 (1.5) 1 (0.5) 48 (24)
Dyspnea 16 (8) 6 (3) 2 (1) 24 (12)
Bronchitis 4 (2) 1 (0.5) 1 (0.5) 6 (3)
Pneumonitis 2 (1) 1 (0.5) 0 (0) 3 (1.5)
ARDS 9 (4.5) 4 (2) 1 (0.5) 14 (7)
Small airway obstruction 16 (8) 10 (5) 8 (4) 34 (17)
ABG abnormality 10 (5) 3 (1.5) 1 (0.5) 14 (7)
Low oxygen saturation 9 (4.5) 4 (2) 1 (0.5) 14 (7)
Chest X-ray abnormality 15 (7.5) 5 (2.5) 3 (1.5) 23 (11.5)
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infected with P. vivax. We suggest increased incidence of
pulmonary manifestation in recent decades.
We observed that 3 (1.5%) malaria patients presented
with pneumonitis. The findings were in accordance with
the incidence observed by Rajput et al13 and Mishra &
Ray12. Our patients presented with fever, chills and cough
which was productive on examination. On sputum culture
examination, this came out to be sterile. On examination
wheeze was present on auscultation. Chest X-ray findings
suggested of bronchitis. In all these patients, there was no
previous history of any respiratory disease and the cough-
ing coincides with onset of fever. Therefore, we concluded
that Plasmodium itself is capable of causing pneumonia.
Tong et al14 and Applebaum et al15 also suggested that
pneumonia presented during malaria is directly contrib-
uted by the disease pathogen itself. Out of 60 patients with
respiratory involvement, 6 (3%) presented with acute bron-
chitis. The previous study conducted by Mishra & Ray12
and Rajput et al13 also observed the same incidence.
ARDS was presented in 14 malaria patients. Our find-
ings were comparatively higher than that seen in studies
of Mishra & Ray12 and Rajput et al13 this may be due to
larger sample size of our study. We observed that in pa-
tients of ARDS, 11 had bilirubin in range of 10–20 mg/dl.
Eight had TLC >11000/μl. These patients present with
abrupt onset of dyspnea, cough, and tightness of chest.
On physical examination these patients presented with
acute respiratory distress, expiratory wheeze and
creptations. Cyanosis was also noticed. X-ray findings in
these patients were suggestive of ARDS and O2 satura-
tion was quite low. Blood gas analysis done on these pa-
tients showed metabolic acidosis. All such patients were
on antimalarials, antibiotics, and ventilator support was
immediately provided. However, none of these patients
survived. This showed that mortality rate in malaria ARDS
is high and it can improve the outcome, if identified timely.
Rajput et al13 observed that ARDS was presented in 4
patients out of 29 with respiratory involvement. Mishra &
Ray12 observed ARDS in 7 cases out of 45 patients with
respiratory involvement. Sarkar et al4 reported three cases
of sudden onset of ARDS from Kolkata as a complication
of P. vivax malaria. Mohan et al16 explained the patho-
genesis of malaria ARDS to be due to erythrocyte seques-
tration and destruction, the release of parasite and eryth-
rocyte material into the circulation, and host response to
these events. Ventilation perfusion mismatch and defect
are most likely functional explanation. Heavy intravascu-
lar monocytic infiltrates provoking inflammatory lesions
to the endothelium of the lungs, but without markerd se-
questration of parasitized red blood cells in the pulmo-
nary microvasculature were histopathologically observed
in a single fatal case of vivax malaria17.
Drug induced reversible small airway obstruction was
observed in 34 patients as assessed by the spirometry. In
patients with pulmonary symptoms, a marked decrease in
PEFR and slowed recovery (9.6 days) was observed10.
Over the last one decade there has been a significant
change in the clinical manifestations of malaria from this
region18. Our study revealed that anemia was present in
33.5% and jaundice in 29% cases. This could be attrib-
uted to changes in the environment due to various causes.
Possibility of changes in the antigenic and pathogenic char-
acteristics of the parasite cannot be ruled out. There re-
main the possibilities of assimilation of the genes respon-
sible for various antigenic attributes by the parasite from
different regions of the country like Bihar, Tripura and
Gujarat.
The awareness about the changing spectrum of se-
vere malaria is of great importance to every level of health
care provider. Our results suggest that pulmonary involve-
ment is seen in a significant number of patients mostly
20–40 yr age group working outside who are most sus-
ceptible, with almost 10% infected with P. vivax. If these
clinical presentations are ignored, it may lead to delay in
diagnosis and can alter the outcome and prognosis of the
disease. Therefore, early diagnosis of malaria induced
ARDS can significantly affect the outcome and may re-
duce the mortality rate associated with this complication.
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